0.10
+0.0148(+17.39%)
Currency In USD
| Previous Close | 0.09 |
| Open | 0.1 |
| Day High | 0.1 |
| Day Low | 0.09 |
| 52-Week High | 206 |
| 52-Week Low | 0.05 |
| Volume | 87,374 |
| Average Volume | 2.6M |
| Market Cap | 102,455 |
| PE | -0.01 |
| EPS | -5.69 |
| Moving Average 50 Days | 1.01 |
| Moving Average 200 Days | 8.72 |
| Change | -0 |
If you invested $1000 in CERo Therapeutics Holdings, Inc. (CERO) since IPO date, it would be worth $0.01 as of December 18, 2025 at a share price of $0.1. Whereas If you bought $1000 worth of CERo Therapeutics Holdings, Inc. (CERO) shares 3 years ago, it would be worth $0 as of December 18, 2025 at a share price of $0.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“
CERo Therapeutics Announces Trading on OTCQB Market
GlobeNewswire Inc.
Dec 02, 2025 12:30 PM GMT
Company’s Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB : CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company develo
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
GlobeNewswire Inc.
Nov 05, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announce